regeneron - Stock Newsroom

S TOCK newsroom .COM

S&P 500 7,393 -0.26%

DJIA 49,641 -0.13%

Nasdaq 28,883 -0.55%

DAX 24,231 -0.62%

Gold $4,196 +0.16%

Oil $102.82 +0.24%

BTC $76,806 -0.13%

VIX 20.28 +0.37%

EUR/USD 1.1785 -0.02%

ETH $2,133 +0.81%

S&P 500 7,393 -0.26%

DJIA 49,641 -0.13%

Nasdaq 28,883 -0.55%

DAX 24,231 -0.62%

Gold $4,196 +0.16%

Oil $102.82 +0.24%

BTC $76,806 -0.13%

VIX 20.28 +0.37%

EUR/USD 1.1785 -0.02%

ETH $2,133 +0.81%

regeneron

Regeneron Melanoma Trial focus with Libtayo cancer drug vial under dramatic clinical lighting

Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock

By Maik Kemper • 16h ago

Regeneron Melanoma Trial focus with Libtayo cancer drug vial under dramatic clinical lighting

Video

Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock

By Maik Kemper • 16h ago

Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik Kemper Editor in Chief Conclusion…